IL6 and systemic-onset juvenile idiopathic arthritis: As the severity of experimental inflammatory arthritis is greatly suppressed in IL-6-/- transgenic mice [115], a promising result was also noted by applying tocilizumab, an IL-6 receptor targeting agent, for the treatment of polyarticular JIA and sJIA [116,117].